Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to 0.23.

  • Enanta Pharmaceuticals' Equity Ratio fell 3259.32% to 0.23 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.23, marking a year-over-year decrease of 3259.32%. This contributed to the annual value of 0.23 for FY2025, which is 3259.32% down from last year.
  • Per Enanta Pharmaceuticals' latest filing, its Equity Ratio stood at 0.23 for Q3 2025, which was down 3259.32% from 0.26 recorded in Q2 2025.
  • Enanta Pharmaceuticals' Equity Ratio's 5-year high stood at 0.93 during Q1 2021, with a 5-year trough of 0.23 in Q3 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' median Equity Ratio value was 0.48 (recorded in 2023), while the average stood at 0.61.
  • As far as peak fluctuations go, Enanta Pharmaceuticals' Equity Ratio tumbled by 77.82% in 2022, and later plummeted by 5132.3% in 2024.
  • Enanta Pharmaceuticals' Equity Ratio (Quarter) stood at 0.87 in 2021, then decreased by 0.78% to 0.87 in 2022, then crashed by 48.27% to 0.45 in 2023, then decreased by 28.38% to 0.32 in 2024, then dropped by 28.12% to 0.23 in 2025.
  • Its Equity Ratio was 0.23 in Q3 2025, compared to 0.26 in Q2 2025 and 0.29 in Q1 2025.